Advanced search
Publication Cover
Natural Product Research
Formerly Natural Product Letters
Latest Articles
Submit an article Journal homepage
93
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of natural products from virtual screenings as SARS-CoV-2 main protease inhibitors using combinational experiments

Jiahao Zhoua Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu, P. R. ChinaView further author information
,
Rui Zhanga Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu, P. R. ChinaView further author information
,
Haohao Yana Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu, P. R. ChinaView further author information
,
Xiaoping Liua Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu, P. R. ChinaView further author information
,
Chao Shangb Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, P. R. ChinaCorrespondence[email protected]
View further author information
&
Yunyu Chena Institute for Drug Screening and Evaluation, Wannan Medical College, Wuhu, P. R. ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2750-8221View further author information
ORCID Icon
Received 24 Oct 2023, Accepted 26 Dec 2023, Published online: 08 Jan 2024

References

  • Anirudhan V, Lee H, Cheng H, Cooper L, Rong L. 2021. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. J Med Virol. 93(5):2722–2734. doi:10.1002/jmv.26814.
  • Banerjee R, Perera L, Tillekeratne LMV. 2021. Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today. 26(3):804–816. doi:10.1016/j.drudis.2020.12.005.
  • Enmozhi SK, Raja K, Sebastine I, Joseph J. 2021. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn. 39(9):3092–3098. doi: 10.1080/07391102.2020.1760136.
  • Ghosh R, Badavath VN, Chowdhuri S, Sen A. 2022. Identification of Alkaloids from Terminalia chebula as potent SARS-CoV-2 main protease inhibitors: an In Silico perspective. ChemistrySelect. 7(14):e202200055. doi:10.1002/slct.202200055.
  • Hassan HA, Abdelmohsen UR, Aly OM, Desoukey SY, Mohamed KM, Kamel MS. 2022. Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies. Nat Prod Res. 36(4):994–998. doi:10.1080/14786419.2020.1839452.
  • Jiang H, Chen J, Li X, Zhong YT, Kang LP, Wang G, Yu M, Fu LF, Wang P, Xu HY. 2023. Systematic identification of chemical components in Fufang Shuanghua oral liquid and screening of potential active components against SARS-CoV-2 protease. J Pharm Biomed Anal. 223:115118. doi:10.1016/j.jpba.2022.115118.
  • Khan A, Heng W, Wang Y, Qiu J, Wei X, Peng S, Saleem S, Khan M, Ali SS, Wei DQ. 2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro). Phytother Res. 35(6):2841–2845. doi:10.1002/ptr.6998.
  • Kubra B, Badshah SL, Faisal S, Sharaf M, Emwas AH, Jaremko M, Abdalla M. 2023. Inhibition of the predicted allosteric site of the SARS-CoV-2 main protease through flavonoids. J Biomol Struct Dyn. 41(18):9103–9120. doi:10.1080/07391102.2022.2140201.
  • Sacco MD, Hu Y, Gongora MV, Meilleur F, Kemp MT, Zhang X, Wang J, Chen Y. 2022. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 32(5):498–500. doi:10.1038/s41422-022-00640-y.
  • Sattari A, Ramazani A, Aghahosseini H. 2021. Repositioning therapeutics for COVID-19: virtual screening of the potent synthetic and natural compounds as SARS-CoV-2 3CLpro inhibitors. J Iran Chem Soc. 18(10):2807–2827. doi:10.1007/s13738-021-02235-7.
  • Xiao T, Cui M, Zheng C, Zhang P, Ren S, Bao J, Gao D, Sun R, Wang M, Lin J, et al. 2022. Both baicalein and gallocatechin gallate effectively inhibit SARS-CoV-2 replication by targeting Mpro and sepsis in mice. Inflammation. 45(3):1076–1088. doi:10.1007/s10753-021-01602-z.
  • Yan G, Li D, Lin Y, Fu Z, Qi H, Liu X, Zhang J, Si S, Chen Y. 2021. Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. Cell Biosci. 11(1):199. doi:10.1186/s13578-021-00720-3.
  • Yan H, Zhang R, Liu X, Wang Y, Chen Y. 2023. Reframing quercetin as a promiscuous inhibitor against SARS-CoV-2 main protease. Proc Natl Acad Sci USA. 120(37):e2309289120. doi:10.1073/pnas.2309289120.
  • Yan H, Zhang R, Yan G, Liu Z, Liu X, Liu X, Chen Y. 2023. Production of a versatile SARS-CoV-2 main protease biosensor based on a dimerization-dependent red fluorescent protein. J Med Virol. 95(1):e28342. doi: 10.1002/jmv.28342.
  • Zarei A, Ramazani A, Pourmand S, Sattari A, Rezaei A, Moradi S. 2022. In silico evaluation of COVID-19 main protease interactions with honeybee natural products for discovery of high potential antiviral compounds. Nat Prod Res. 36(16):4254–4260. doi:10.1080/14786419.2021.1974435.
  • Zhang J, Yan H, Yan G, Liu X, Wang Y, Chen Y. 2022. Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay. STAR Protoc. 3(4):101794. doi:10.1016/j.xpro.2022.101794.
  • Zhang R, Yan H, Yan G, Liu X, Chen Y. 2023. Repurposing tafenoquine as a potential inhibitor against severe acute respiratory syndrome coronavirus 2 main protease via a fluorescence polarization assay. Assay Drug Dev Technol. 21(8):369–371. doi:10.1089/adt.2023.103.
  • Zhang R, Yan H, Zhou J, Liu X, Chen Y. 2023. Invalidation of geraniin as a potential inhibitor against SARS-CoV-2 main protease. Nat Prod Res. 2023:1–4. doi:10.1080/14786419.2023.2241973.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.